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HIF2a inhibitors for the treatment of VHL disease 
Ana Martins Metelo, Haley Noonan and Othon Iliopoulos
Patients with von Hippel-Lindau (VHL) disease 
possess a germline mutation in the VHL tumor suppressor 
gene that confers a life-time risk of developing renal 
cell carcinomas (RCC), central nervous system 
hemangioblastomas (HB), pheochromocytomas, 
pancreatic neuroendocrine tumors, papillary cystadenomas 
and erythrocytosis [1]. The VHL protein targets the 
Hypoxia Inducible Factors 1 and 2a (HIF1a and HIF2a) 
for proteasomal degradation in cells exposed to a normal 
range of oxygen concentration. However, low oxygen 
concentration (hypoxia) or loss-of-VHL function lead to 
HIF1a/2a stabilization and transactivation of HIF-target 
genes. HIF1a/2a are transcription factors targeting genes 
such as vascular endothelial factor (VEGF), transforming 
growth factor (TGF), erythropoietin (EPO), erythropoietin 
receptor (EPOR), transferrin, and angiopoietin 1. 
Collectively, the expression of HIF1a/2a target genes 
contributes to oncogenic processes such as angiogenesis, 
erythropoiesis, reprogramming of metabolism, cell 
proliferation, and metastasis [1]. HIF1a and HIF2a are 
paralogs expressed in most human epithelial cells and 
possess both overlapping and distinct functions [2]. 
For example, in RCC, it is known that HIF2a acts as an 
oncogene, while HIF1a is a tumor suppressor gene [3].  
There are currently no drugs available to treat VHL 
disease. VHL patients develop multiple tumors over a 
lifetime that require repeated surgeries. Not only can such 
surgeries for serially appearing lesions result in damaged 
renal or brain parenchyma, but oftentimes they are not 
feasible due to the location of the HB [4]. Therefore, 
pharmacological inhibition of HIF2a would be an ideal 
therapeutic strategy in the treatment of VHL disease and 
HIF2a-driven tumors. We review here our recent work 
and present for the first time evidence that small molecule 
HIF2a inhibitors, developed by the Iliopoulos Laboratory 
at Massachusetts General Hospital and Harvard Medical 
School, target HIF2a in vivo, using a vertebrate animal 
model of human VHL disease. 
We previously identified small molecule HIF2a 
inhibitors via a mammalian cell-based reporter screen of 
HIF2a activity [5]. These inhibitors operate by enhancing 
the binding of iron regulatory protein 1 (IRP1) to an iron 
regulatory element (IRE) in the 5’-UTR of HIF2a, but 
not HIF1a mRNA, thereby specifically repressing HIF2a 
translation. In our recent study, published in Journal of 
Clinical Investigation (Metelo AM et al., JCI 2015;125 
(5):1987-97), we provide evidence that the HIF2a 
inhibitor, lead compound 76, can inhibit the zebrafish 
orthologs of human HIF2a and ameliorates significantly 
the phenotypic abnormalities of the vhl-/- embryos. This 
work indicates that pharmacological inhibition of HIF2a 
is sufficient to treat VHL-disease related abnormalities. In 
addition, it provides strong rational for further preclinical 
development of these HIF2a inhibitors.
Zebrafish possess two orthologs of human HIF2a, 
called epas1a and epas1b, as well as two orthologs 
of human HIF1a, hif1aa and hif1ab. We previously 
showed that only human HIF2a contains a 5’-UTR 
with a functional IRE, unlike HIF1a, and consequently, 
compound 76 is specific for HIF2a and does not suppress 
HIF1a translation in mammalian cells [5]. We proved 
that the same is true for the 5’-UTR of zebrafish Hif2a 
orthologs, epas1a and epas1b.
To test whether compound 76 has the ability to 
repress epas1a and epas1b activity in vivo we challenged 
wild type zebrafish embryos with a chemical hypoxia 
mimetic, DMOG. Treatment of animals with DMOG 
results in stabilization of all zebrafish orthologs of 
human HIF1a/2a and robust upregulation of their target 
genes (phd3, epo, and vegfab). Compound 76 suppressed 
the expression of hypoxia-target genes in zebrafish. 
Morpholino knockdown experiments strongly suggest that 
hypoxic expression of epo and vegf is primarily controlled 
by the Hif2a paralogs, epas1a and epas1b. Suppression 
of epas1a and epas1b by compound 76 was biologically 
impactful; compound 76 significantly suppressed the 
epo-driven erythrocytosis and angiogenesis that followed 
exposure of embryos to DMOG. 
In the process of quantifying the effect of inhibitor 
76 we developed, in collaboration with the Carpenter 
Laboratory at the Broad Institute, a computerized image-
based assay that allows the quantification of angiogenesis 
and erythropoiesis in zebrafish embryos. This novel 
method can now be applied to high-throughput screens for 
the identification of compounds that regulate angiogenesis 
and erythropoiesis in vivo. 
Zebrafish embryos, homozygous for vhl loss-of-
function mutations (vhl-/-  embryos), resemble human 
VHL disease and develop epo-driven erythrocytosis, 
complex blood vessel networks in the brain and retina 
reminiscent of HB, increased proliferation of their liver 
and kidney that is reflective of VHL-associated tumor 
biology, and cardiomegaly with decreased cardiac 
contractility [6]. We used vhl-/- embryos to test the in vivo 
effect of the HIF2a inhibitors that we identified. We found 
that compound 76 significantly suppresses the expression 
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of epas1a/1b-target genes (phd3, epo, transferrin, vegfab, 
angiopoietin 1, and tgfa) in vhl-/- mutant embryos. The 
effect of the inhibitor was not merely biochemical; 
compound 76 suppressed the epo-driven erythrocytosis 
as well as the abnormal vascular proliferation seen in 
the brain and trunk characterizing the vhl-/- embryos. In 
addition, compound 76 promoted erythroid differentiation 
and decreased the number of early erythroid progenitors 
circulating in the peripheral blood. The number of 
erythroid progenitors is characteristically increased in 
vhl-/- embryos, possibly as a direct effect of epas1a/1b 
on erythroid maturation. Finally, we found that the HIF2a 
inhibitor compound 76 significantly improved cardiac 
contractility among the vhl-/- embryos and enhanced their 
viability.
In conclusion, our work presents an example 
of pharmacological treatment of VHL disease related 
abnormalities in a vertebrate animal model. HIF2a 
inhibitor 76, a lead compound, exhibits promising in vivo 
activity as it can partially reverse the VHL phenotype 
in zebrafish. These observations provide a strong 
rationale for optimization of compound 76 via medicinal 
chemistry to develop derivatives suitable for preclinical 
and clinical testing. The VHL gene is inactivated in 
over 90% of sporadic RCC tumors [7], rendering RCC 
a model disease for HIF2a inactivation. Specific HIF2a-
inhibitors can be used not only to treat VHL disease but 
the majority of these sporadic RCC as well. In addition, 
there is compelling preclinical and clinical evidence for 
the contribution of HIF2a expression in several human 
malignancies (such as glioblastoma, lung, colon, ovarian 
and prostate cancer).
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